丽珠医药（01513）公布，鉴于公司 2022 年股票期权激励计划首次授予股票期权第二个行权期（期权合计 528.375 万份）及预留授予第一个行权期（期权合计 100.00 万份）对应公司层面业绩不达标，当期期权不得行权。公司董事会同意对上述股票期权共计 628.375 万份予以注销。
丽珠医药拟注销628.375万份股票期权
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.